MSD Contact Information Legal Terms MSD Jobs
MESO SCALE DISCOVERY
MESO SCALE DISCOVERY
Catalog
MULTI-ARRAY Detection Technology
Products
Literature & Publications
Applications Literature
Brochures
Customer Presentations
MSD Assay Product Inserts
Technical & Application Notes
MSD Publication References
Our Company
Purchase MSD Assays
Shows & Events We Attend
 



Publications

Microglial p38α MAPK is a key regulator of proinflammatory cytokine up-regulation induced by toll-like receptor (TLR) ligands or beta-amyloid (Aβ).

Bachstetter, A.D., Xing, B., de Almeida, L., Dimayuga, E.R., Watterson, D.M., van Eldik, L.J.

Journal J Neuroinflammation. Year 2011
Species Mouse Volume 8
IL-1β, TNF-α Page # 79
Matrix Tested Cell culture supernatants, Serum, Brain homogenates

Abstract

Background

Overproduction of proinflammatory cytokines from activated microglia has been implicated as an important contributor to pathophysiology progression in both acute and chronic neurodegenerative diseases. Therefore, it is critical to elucidate intracellular signaling pathways that are significant contributors to cytokine overproduction in microglia exposed to specific stressors, especially pathways amenable to drug interventions. The serine/threonine protein kinase p38α MAPK is a key enzyme in the parallel and convergent intracellular signaling pathways involved in stressor-induced production of IL-1β and TNFα in peripheral tissues, and is a drug development target for peripheral inflammatory diseases. However, much less is known about the quantitative importance of microglial p38α MAPK in stressor-induced cytokine overproduction, or the potential of microglial p38α MAPK to be a druggable target for CNS disorders. Therefore, we examined the contribution of microglial p38αMAPK to cytokine up-regulation, with a focus on the potential to suppress the cytokine increase by inhibition of the kinase with pharmacological or genetic approaches.

Methods The microglial cytokine response to TLR ligands 2/3/4/7/8/9 or to Aβ1-42 was tested in the presence of a CNS-penetrant p38α MAPK inhibitor, MW01-2-069A-SRM. Primary microglia from mice genetically deficient in p38α MAPK were used to further establish a linkage between microglia p38α MAPK and cytokine overproduction. The in vivo significance was determined by p38α MAPK inhibitor treatment in a LPS-induced model of acute neuroinflammation.

Results Increased IL-1β and TNFα production by the BV-2 microglial cell line and by primary microglia cultures was inhibited in a concentration-dependent manner by the p38α MAPK-targeted inhibitor. Cellular target engagement was demonstrated by the accompanying decrease in the phosphorylation state of two p38α MAPK protein substrates, MK2 and MSK1. Consistent with the pharmacological findings, microglia from p38α-deficient mice showed a diminished cytokine response to LPS. Further, oral administration of the inhibitor blocked the increase of IL-1β in the cerebral cortex of mice stressed by intraperitoneal injection of LPS.

Conclusion The p38α MAPK pathway is an important contributor to the increased microglial production of proinflammatory cytokines induced by diverse stressors. The results also indicate the feasibility of targeting p38α MAPK to modulate CNS proinflammatory cytokine overproduction.Keywords: Microglia, cytokines, toll-like receptors, knockout mice, p38alpha mitogen-activated protein kinase, amyloid beta-peptides, drug discovery.

View Publication


Related Products
Mouse ProInflammatory 7-Plex Base Kit
Mouse ProInflammatory 7-Plex Tissue Culture Kit
Mouse ProInflammatory 7-Plex Ultra-Sensitive Kit
Mouse TH1/TH2 9-Plex Base Kit
Mouse TH1/TH2 9-Plex Tissue Culture Kit
Mouse TH1/TH2 9-Plex Ultra-Sensitive Kit
MA6000 Mouse IL-1b 384 Tissue Culture Kit
MA6000 Mouse TNF-a 384 Tissue Culture Kit
Mouse IL-1beta 384 Tissue Culture Kit
Mouse IL-1beta Base Kit

view more

Suggest a Reference


Speak with a Scientist



CAREERS     |     CONTACT US     |     LEGAL     |     PRIVACY
Feedback Form
Feedback Analytics